Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Did Hedge Funds Drop The Ball On Casa Therapeutics Inc (CARA) ?

At Insider Monkey, we pore over the filings of nearly 750 top investment firms every quarter, a process we have now completed for the latest reporting period. The data we’ve gathered as a result gives us access to a wealth of collective knowledge based on these firms’ portfolio holdings as of December 31. In this article, we will use that wealth of knowledge to determine whether or not Casa Therapeutics Inc (NASDAQ:CARA) makes for a good investment right now.

Casa Therapeutics Inc (NASDAQ:CARA) was in 9 hedge funds’ portfolios at the end of the fourth quarter of 2018. CARA shareholders have witnessed a decrease in hedge fund sentiment in recent months. There were 11 hedge funds in our database with CARA positions at the end of the previous quarter. Our calculations also showed that cara isn’t among the 30 most popular stocks among hedge funds.

According to most investors, hedge funds are seen as unimportant, outdated investment tools of the past. While there are over 8000 funds trading at the moment, We look at the elite of this group, around 750 funds. These investment experts preside over the lion’s share of all hedge funds’ total asset base, and by tailing their highest performing picks, Insider Monkey has figured out numerous investment strategies that have historically outstripped the S&P 500 index. Insider Monkey’s flagship hedge fund strategy defeated the S&P 500 index by nearly 5 percentage points per year since its inception in May 2014 through early November 2018. We were able to generate large returns even by identifying short candidates. Our portfolio of short stocks lost 27.5% since February 2017 (through March 12th) even though the market was up nearly 25% during the same period. We just shared a list of 6 short targets in our latest quarterly update and they are already down an average of 6% in less than a month.


Let’s view the new hedge fund action regarding Casa Therapeutics Inc (NASDAQ:CARA).

How are hedge funds trading Casa Therapeutics Inc (NASDAQ:CARA)?

At the end of the fourth quarter, a total of 9 of the hedge funds tracked by Insider Monkey were long this stock, a change of -18% from one quarter earlier. On the other hand, there were a total of 5 hedge funds with a bullish position in CARA a year ago. So, let’s check out which hedge funds were among the top holders of the stock and which hedge funds were making big moves.

No of Hedge Funds with CARA Positions

Among these funds, Renaissance Technologies held the most valuable stake in Casa Therapeutics Inc (NASDAQ:CARA), which was worth $5.4 million at the end of the fourth quarter. On the second spot was Marshall Wace LLP which amassed $4.3 million worth of shares. Moreover, Millennium Management, DAFNA Capital Management, and Citadel Investment Group were also bullish on Casa Therapeutics Inc (NASDAQ:CARA), allocating a large percentage of their portfolios to this stock.

Seeing as Casa Therapeutics Inc (NASDAQ:CARA) has witnessed declining sentiment from the entirety of the hedge funds we track, we can see that there lies a certain “tier” of hedgies that elected to cut their entire stakes in the third quarter. It’s worth mentioning that Ori Hershkovitz’s Nexthera Capital dumped the largest investment of the 700 funds monitored by Insider Monkey, totaling an estimated $17.7 million in stock, and James A. Silverman’s Opaleye Management was right behind this move, as the fund said goodbye to about $3.1 million worth. These moves are important to note, as aggregate hedge fund interest was cut by 2 funds in the third quarter.

Let’s also examine hedge fund activity in other stocks similar to Casa Therapeutics Inc (NASDAQ:CARA). These stocks are First Community Bankshares Inc (NASDAQ:FCBC), National CineMedia, Inc. (NASDAQ:NCMI), ADTRAN, Inc. (NASDAQ:ADTN), and Precision Drilling Corp (NYSE:PDS). All of these stocks’ market caps are closest to CARA’s market cap.

Ticker No of HFs with positions Total Value of HF Positions (x1000) Change in HF Position
FCBC 3 8781 -1
NCMI 19 30087 4
ADTN 15 37702 7
PDS 14 29983 -1
Average 12.75 26638 2.25

View table here if you experience formatting issues.

As you can see these stocks had an average of 12.75 hedge funds with bullish positions and the average amount invested in these stocks was $27 million. That figure was $17 million in CARA’s case. National CineMedia, Inc. (NASDAQ:NCMI) is the most popular stock in this table. On the other hand First Community Bankshares Inc (NASDAQ:FCBC) is the least popular one with only 3 bullish hedge fund positions. Casa Therapeutics Inc (NASDAQ:CARA) is not the least popular stock in this group but hedge fund interest is still below average. Our calculations showed that top 15 most popular stocks) among hedge funds returned 24.2% through April 22nd and outperformed the S&P 500 ETF (SPY) by more than 7 percentage points. A small number of hedge funds were also right about betting on CARA as the stock returned 36.2% and outperformed the market by an even larger margin.

Disclosure: None. This article was originally published at Insider Monkey.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.